Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcome. BPDCN diagnostically overlaps with entities such as acute myeloid leukemia, histiocytic/dendritic cell neoplasms, and NK/T cell lymphomas. Unfortunately, large patient centered studies that comprehensively analyze clinical, pathologic and other diagnostic features are lacking. As such, there is an incomplete understanding of this disease. To better characterize BPDCN, a multicenter working group consisting of hematopathologists and dermatopathologists gathered in-person and remotely to review the current understanding of BPDCN, discuss specific issues regarding the diagnosis and differential diagnosis, and perform a retrospective analysis of the literature. A curated database of published BPDCN patient cases (BPDCN Network literature database) was generated. By conducting an in-depth analysis, not only did we confirm known findings in BPDCN such as frequent skin involvement and male predominance amongst older patients, but we also identified a number of under-recognized features, such as significant central nervous system involvement (35% of cases), and a roughly equal female to male prevalence amongst patients < 40 years old. Furthermore, with the large database, we were able to accurately summarize the immunohistochemical, cytogenetic, and molecular features of this disease. The BPDCN Network literature database serves as a central data repository of archived published aggregated and individual cases and facilitates an in-depth characterization of this rare disease. Continual updates from the consortium and beyond will allow for prospective refinement of our understanding of this orphan disease.
Ohgami: Stemline Therapeutics: Research Funding. Aung: Stemeline Therapeutics: Honoraria. Gru: Innate Pharma: Research Funding; StemLine: Honoraria, Research Funding, Speakers Bureau; CRISPT Therapeutics: Research Funding. Hussaini: Stemeline Therapeutics: Honoraria. Jaye: Stemline Therapeutics: Honoraria. Wang: Stemline Therapeutics: Honoraria. Pullarkat: Stemline Therapeutics: Honoraria. George: Bristol Meyers Squibb: Consultancy; Incyte Corporation: Consultancy; Blueprint Medicines: Consultancy; Celgene: Consultancy.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal